Ipilimumab (NCT05779423)

Name: Ipilimumab trial for Metastatic Melanoma (NCT05779423)
Uploaded: 2026-10-31T16:55:14.084Z
Duration: 1 min 18 s
Description: Ipilimumab trial for Metastatic Melanoma (NCT05779423). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05779423.

Cryoablation+Ipilimumab+Nivolumab in Melanoma: a one-minute explainerNCT057794231 min

Ipilimumab trial for Metastatic Melanoma (NCT05779423). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients older than 18 with unresectable melanoma progressing after checkpoint immunotherapy. Progression on ipilimumab plus nivolumab as the latest treatment excludes participation.

The idea: intravenous ipilimumab and nivolumab release immune brakes through CTLA-4 and PD-1. Between the first two cycles, a needle biopsy is followed by freezing one accessible tumor. Another measurable tumor must remain for assessment. Researchers test clinical benefit and safety of this combination.

This phase 2 study plans 37 patients. Meghan Mooradian leads at Massachusetts General Hospital in Boston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.